Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14557426 | 0.87 | CA1 (0.38) | CA1CA2 | |
| SCHEMBL18083196 | 0.77 | CA1 (0.50) | CA1CA2 | |
| SCHEMBL14450355 | 0.75 | CA1 (0.41) | CA1CA2TSHR | |
| SCHEMBL1446184 | 0.73 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL14040885 | 0.73 | CA1 (0.40) | CA1CA2 | |
| SCHEMBL862360 | 0.71 | — | — | |
| SCHEMBL2057335 | 0.71 | — | — | |
| SCHEMBL245242 | 0.71 | — | — | |
| SCHEMBL1937404 | 0.71 | — | — | |
| SCHEMBL12823569 | 0.71 | CCR5 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417864-A1 | ELECTROCHEMICAL REDUCTIVE CARBOXYLATION OF UNSATURATED ORGANIC SUBSTRATES IN IONICALLY CONDUCTIVE MEDIUMS | UNIV MICHIGAN STATE (US) | 2024-12-19 | — | — | US | disclosed |
| US-11851778-B2 | Electrochemical reductive carboxylation of unsaturated organic substrates in ionically conductive mediums | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-12-26 | — | — | US | disclosed |
| US-20200181782-A1 | ELECTROCHEMICAL REDUCTIVE CARBOXYLATION OF UNSATURATED ORGANIC SUBSTRATES IN IONICALLY CONDUCTIVE MEDIUMS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2020-06-11 | — | — | US | disclosed |
| WO-2019023532-A1 | ELECTROCHEMICAL REDUCTIVE CARBOXYLATION OF UNSATURATED ORGANIC SUBSTRATES IN IONICALLY CONDUCTIVE MEDIUMS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2019-01-31 | — | — | WO | disclosed |
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008011521-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| WO-2005026136-A2 | 2, 2'-AZINO-BIS-THIAZOLINES AND USES THEREOF AS AIR- AND WATER- STABLE RADICAL PRECURSORS | ARMAND MICHEL (FR) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | QDPR, NQO2, DHPS | CA1 3910/4885CA2 3290/4885TSHR 806/4885 |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | CA1 4504/4885CA2 3882/4885TSHR 4802/4885 |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | CA1 4078/4885CA2 2963/4885TSHR 555/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | CA1 4754/4885CA2 4389/4885TSHR 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.